About HealthCare Global Enterprises Limited

HealthCare Global Enterprises Limited (HCG) is India’s largest oncology-focused healthcare provider, founded over 35 years ago with a single centre in Bengaluru and now operating a network of 22 comprehensive cancer centres, multispecialty hospitals, and advanced diagnostics across 19 cities as of March 31, 2025. HCG delivers end-to-end cancer care from screening and diagnosis to advanced therapies and survivorship, anchored by precision oncology through its integrated genomics, proteomics, and real‑world data platform. The Group operates specialised divisions including Triesta Sciences (oncology diagnostics), Milann (reproductive medicine), and multispecialty hospitals, supported by 400 oncologists and 1,287 ICU beds, having treated 9.5 lakh cancer patients in the last five years and completed 4,246 successful IVF cycles in FY 2024‑25. HCG’s operating footprint is pan‑India with infusion facilities and PET‑CT capabilities, complemented by technology leadership with systems such as Agility Synergy, Versa HD, TomoTherapy, and adaptive radiotherapy platforms to enhance first‑time‑right treatments. The Company and subsidiaries include entities such as HCG Medi‑Surge Hospitals Private Limited, HCG Oncology LLP, HCG Manavata Oncology LLP, HCG NCHRI Oncology LLP, HCG Kolkata Cancer Care LLP, BACC Healthcare Private Limited (Milann), HCG Mauritius Pvt Ltd, and others, with a consolidated roster of over a dozen material subsidiaries and LLPs as disclosed in AOC‑1 for FY 2024‑25. Key milestones include geographic expansion to 19 cities, diagnostics scale‑up via Triesta (CAP and NABL accredited network), and integration of precision oncology into clinical pathways across centres, driving improved outcomes and reduced toxicities through targeted, evidence‑based care.

HealthCare Global Enterprises Limited Business Segment

• Oncology care: Comprehensive cancer centres offering medical, surgical, and radiation oncology, precision diagnostics, and immuno‑ and targeted therapies at scale across India.

• Diagnostics (Triesta Sciences): Integrated oncology diagnostics covering routine to advanced molecular and genetic assays, enabling clinician decision support and personalised protocols with CAP/NABL accreditations nationwide.

• Reproductive medicine (Milann): Assisted Reproductive Technology, reproductive endocrinology, and genetics, with decades of expertise and pan‑India patient inflow; 4,246 successful IVF cycles in FY 2024‑25.

• Multispecialty hospitals: Advanced tertiary care in cardiac sciences, orthopaedics, neuro sciences, nephrology, gastroenterology, and critical care, integrated with oncology where relevant.
  

HealthCare Global Enterprises Limited Key Management

• Dr. B. S. Ajaikumar — Non‑Executive Chairman (also referred as Executive Chairman in remuneration table context for FY figures).

• Dr. Manish Mattoo — Executive Director and Chief Executive Officer (noted in Board signatory block dated May 24, 2025).

• Anjali Ajaikumar Rossi — Executive Director (also detailed as Non‑Executive Director in a later AGM notice context; designation to be taken as Executive Director per leadership listing and Board signatory).

• Ruby Ritolia — Chief Financial Officer.

• Sunu Manuel — Company Secretary.
  

Latest Updates on HealthCare Global Enterprises Limited

• Acquisition of stake in Vizag Hospital and Cancer Research Centre Private Limited, adding one subsidiary and two step‑down subsidiaries during FY 2024‑25, with integration of IT systems planned post‑April 2026 following upgrade decisions for HIS and SAP financials.

• Solar power project: Commissioning of a 2.25 MW solar plant at Jagaluru, Davangere, Karnataka, to supply HCG KR Road, Bengaluru, and HCG Suchirayu, Hubli; expected generation of 1,040 lakh units over 25 years, ~76,200 metric tons CO2 reduction, and annual savings up to Rs 4.20 crore.

• ESOP 2021 amendment approved by shareholders on April 27, 2025, enabling surrender and cash settlement for up to 16,19,741 options around trade sale scenarios per specified terms.

• Appointment of Ms. V. Sreedharan Associates as Secretarial Auditors for a five‑year term commencing FY 2025‑26, subject to members’ approval, with prior MR‑3 and compliance reports annexed.

• Re‑appointment of cost auditors and proposed remuneration of Rs 2.50 lakh for FY 2025‑26, subject to ratification at the ensuing AGM.